QUEBEC, Aug. 21 /CNW Telbec/ - Dr. Jean-Pierre Grégoire, Dean of the
Faculty of Pharmacy, Université Laval and Chair, 2007 Scientific Program the
23rd International Conference on Pharmacoepidemiology & Therapeutic Risk
Management, will introduce University of Montreal Clinical Associate Julie
Blouin, winner of the ISPE 2007 Best Drug Utilization Abstract Tuesday
August 21 at 11 a.m.
Blouin's study, conducted under the supervision of Dr. Sylvie Perrault,
demonstrates an increased incidence of osteoporotic fractures following
non-adherence to bisphosphonates drug therapy in post-menopausal women. The
study is based on an analysis involving 3293 cases of fractures which
indicates that post-menopausal women who showed a less than 80% adherence to
treatment suffered an increased incidence of fractures.
One woman in four over the age of 50 suffers from osteoporosis. In fact,
the number of women affected by hip fractures is quite alarming. There are
approximately 25,000 hip fractures in Canada each year, with 70% being related
to osteoporosis. Costs related to osteoporosis amount to $1.9 billion dollars
each year in Canada. Given the aging population, it is estimated that this
cost will rise to $32.5 billion dollars by 2018, if no effective prevention
and treatment strategies are set in place.
Julie Blouin, Dr. Jean-Pierre Grégoire, Dr. Sylvie Perrault and Dr. Yola
Moride, President-elect of the International Society of Pharmacoepidemiology
(ISPE), will be available to answer questions concerning the study and the
role of Drug Risk Management.
When: 11 a.m. Tuesday August 21, 2007
Where: Room 204A, Québec City Convention Centre,
1000, boul. René-Lévesque EST, Québec, QC
For further information:
For further information: www.pharmacoepi.org; Source: Charles Pitts,
(514) 984-5614, firstname.lastname@example.org